Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP)’s share price dropped 1.8% on Monday . The stock traded as low as $13.05 and last traded at $13.15, with a volume of 142,465 shares trading hands. The stock had previously closed at $13.39.

AQXP has been the subject of several recent research reports. Jefferies Group lifted their price target on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the company a “hold” rating in a research report on Friday, August 5th. Zacks Investment Research cut Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. Finally, Canaccord Genuity set a $22.00 target price on Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, July 21st. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. Aquinox Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $19.86.

The company has a 50-day moving average of $10.63 and a 200-day moving average of $8.65. The firm’s market capitalization is $231.16 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its earnings results on Thursday, August 4th. The company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.22. On average, equities analysts predict that Aquinox Pharmaceuticals Inc. will post ($2.11) EPS for the current year.

Institutional investors have recently made changes to their positions in the company. Boxer Capital LLC boosted its position in shares of Aquinox Pharmaceuticals by 7.0% in the second quarter. Boxer Capital LLC now owns 877,753 shares of the company’s stock worth $5,811,000 after buying an additional 57,738 shares in the last quarter. Bridgeway Capital Management Inc. boosted its position in shares of Aquinox Pharmaceuticals by 416.7% in the second quarter. Bridgeway Capital Management Inc. now owns 62,000 shares of the company’s stock worth $410,000 after buying an additional 50,000 shares in the last quarter. Opaleye Management Inc. bought a new position in shares of Aquinox Pharmaceuticals during the second quarter worth approximately $1,953,000. BlackRock Fund Advisors boosted its position in shares of Aquinox Pharmaceuticals by 1.8% in the second quarter. BlackRock Fund Advisors now owns 228,693 shares of the company’s stock worth $1,514,000 after buying an additional 3,977 shares in the last quarter. Finally, BlackRock Advisors LLC boosted its position in shares of Aquinox Pharmaceuticals by 2.1% in the second quarter. BlackRock Advisors LLC now owns 404,575 shares of the company’s stock worth $2,678,000 after buying an additional 8,280 shares in the last quarter. 89.41% of the stock is currently owned by institutional investors.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

5 Day Chart for NASDAQ:AQXP

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.